Hatching from the cocoon: US FDA embraces the world
This article was originally published in Scrip
Executive Summary
Facing the reality that 80% of the active ingredients in prescription drugs consumed by the US public comes from overseas, let alone a large portion of the nation's food supply, the US FDA in recent years has been taking steps to move from being mostly a homeland-focused regulator to engaging the rest of the world – breaking out of its insulated cocoon at its White Oak compound in Silver Spring, Maryland and setting up shop where the action is, like Mumbai, India; Guangzhou, China; Amman, Jordan; Pretoria, South Africa; and Santiago, Chile.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.